Every Form 4 that Centessa Pharmaceuticals Plc (CNTA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CNTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNTA filings page.
Medicxi Ventures Management (Jersey) Ltd reported open-market sale transactions in this Form 4 filing.
Centessa Pharmaceuticals plc disclosed that investment entities affiliated with Medicxi completed the transfer of a total of 19,963,157 Ordinary Shares in connection with the acquisition of Centessa by Eli Lilly and Company. The transfer occurred automatically at the effective time of a UK Scheme of Arrangement, not through discretionary open-market trading by the reporting entities.
Under the deal, each Ordinary Share (and each ADS representing one Ordinary Share) entitled holders to receive $38.00 in cash per share, plus one non-transferable contingent value right for potential additional payments of up to $9.00 per share upon achievement of specified milestones. Following these transactions, the reported Medicxi-related holdings of Centessa Ordinary Shares decreased to zero, and the reporting persons note they disclaim beneficial ownership except to the extent of any pecuniary interest.
INDEX VENTURES LIFE VI (JERSEY) L.P. reported open-market sale transactions in this Form 4 filing.
Centessa Pharmaceuticals plc reported that investment entities associated with Index Ventures completed the transfer of 9,961,789 Ordinary Shares in connection with the company’s acquisition by Eli Lilly and Company. The shares, held indirectly through Index Ventures Life VI (Jersey) L.P. and Yucca (Jersey) SLP, moved automatically at the effective time of a UK Scheme of Arrangement, rather than through a discretionary market trade.
At the effective time, each Ordinary Share became entitled to receive $38.00 in cash per share, plus one non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share, subject to specified milestones. The reporting persons disclaim beneficial ownership of these securities except to the extent of any pecuniary interest.
Centessa Pharmaceuticals’ Chief Legal Officer, Iqbal J. Hussain, reported the automatic disposition of his equity in connection with Eli Lilly’s acquisition of Centessa. On June 24, 2026, all of his Ordinary Shares and share options, including 5,500 shares held indirectly by his spouse and 117,645 shares held directly, were transferred pursuant to a court-approved scheme of arrangement.
At the effective time, each Ordinary Share (and each ADS representing one Ordinary Share) became entitled to receive $38.00 in cash plus one non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share, subject to specified milestones. His unvested RSUs, covering 98,025 Ordinary Shares, fully vested and, along with all outstanding options, were cancelled and converted into the same cash-and-CVR package rather than being exercised.
Centessa Pharmaceuticals plc Chief Technology & Quality Officer Tia L. Bush reported the automatic disposition of her equity in connection with Eli Lilly and Company’s acquisition of all outstanding Centessa ordinary shares. Bush’s 147,954 Ordinary Shares and all reported share options were transferred to the acquirer under a UK scheme of arrangement, leaving her with zero directly held shares and options after the transactions.
At the effective time of the scheme, holders of Ordinary Shares became entitled to receive $38.00 in cash per share, less applicable taxes, plus one non-transferable contingent value right (CVR) for each share. Each CVR provides for potential contingent payments of up to an aggregate of $9.00 per share, subject to specified milestones. The same per-share terms apply to American Depositary Shares, each representing one Ordinary Share. Unvested restricted share units fully vested and, along with share options, were cancelled and converted into the right to receive the cash consideration and one CVR per underlying Ordinary Share.
Centessa Pharmaceuticals plc Chief Financial Officer John J. Crowley reported dispositions of his equity in connection with the acquisition of Centessa by Eli Lilly and Company. On June 24, 2026, Eli Lilly, through a subsidiary, acquired all outstanding Centessa Ordinary Shares via a UK scheme of arrangement.
At the effective time, holders of Ordinary Shares became entitled to receive $38.00 in cash per Ordinary Share plus one contingent value right (CVR) for potential additional payments of up to $9.00 per Ordinary Share. The same terms applied per American Depositary Share.
Crowley disposed of 45,000 Ordinary Shares and had his Restricted Share Units and share options automatically cancelled and converted into rights to receive the cash consideration and one CVR per underlying share. The footnotes state these transfers occurred automatically under the Transaction Agreement, without any action or discretion by Crowley.
Centessa Pharmaceuticals’ Chief People Officer Karen M. Anderson reported the automatic disposition of all her equity in connection with Eli Lilly’s acquisition of the company. On the effective date of the UK court-approved scheme of arrangement, all her 62,085 Ordinary Shares transferred to Lilly.
Each Ordinary Share entitled the holder to receive $38.00 in cash plus a non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share, subject to specified milestones. Unvested RSUs covering 58,050 Ordinary Shares fully vested and were similarly cancelled for cash and CVRs.
All outstanding share options held by Anderson, including grants over 117,000, 120,000, 83,924, 28,336 and 75,000 Ordinary Shares at various exercise prices, were cancelled and converted into cash equal to the excess of the $38.00 cash consideration over each option’s exercise price, plus one CVR per underlying share. Following these transactions, she reported no remaining Ordinary Shares or options.
Centessa Pharmaceuticals' Chief Accounting Officer Raphael Deferiere reported the automatic disposition of his equity holdings in connection with Eli Lilly’s acquisition of the company. He disposed of 11,000 Ordinary Shares and options over 42,000 and 165,000 Ordinary Shares, leaving no remaining reported holdings.
Under a UK Scheme of Arrangement, Eli Lilly acquired all outstanding Centessa Ordinary Shares. At the effective time, holders became entitled to receive $38.00 in cash per Ordinary Share plus one contingent value right (CVR) for potential additional payments of up to $9.00 per share. RSUs and options were cancelled and converted into the right to receive the same cash and CVR-based consideration, and no discretionary trades were made by the reporting person.
Centessa Pharmaceuticals Chief Medical Officer Stephen Kanes reported the automatic disposition of his equity in connection with Eli Lilly’s acquisition of the company. He disposed of 120,000 Ordinary Shares and 500,000 share options to the issuer, leaving him with no reported holdings.
Under a UK Scheme of Arrangement, Eli Lilly, through a subsidiary, acquired all outstanding Centessa Ordinary Shares. At the effective time, each share became entitled to receive $38.00 in cash plus one non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share.
Restricted Share Units and options held by Kanes were cancelled and converted into cash and CVRs in line with the transaction terms, with options paid in cash equal to the excess of the $38.00 cash consideration over the $16.90 per-share exercise price, plus one CVR for each underlying Ordinary Share.
Centessa Pharmaceuticals CEO Mario Alberto Accardi reported the automatic disposition of his equity in Centessa following its acquisition by Eli Lilly and Company. All 243,282 Ordinary Shares, which may be represented by ADSs, were transferred at the effective time of a court-approved Scheme of Arrangement.
Each Ordinary Share entitled the holder to receive $38.00 in cash plus one non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share, subject to specified milestones. In addition, 81,806 Ordinary Shares underlying RSUs became fully vested and were converted into the same cash-and-CVR package.
All outstanding share options held by Accardi, across multiple grants with exercise prices ranging from $3.85 to $25.19, were automatically cancelled and converted into cash equal to the excess of the $38.00 cash consideration over each option’s exercise price, plus one CVR per underlying share. No shares or options were exercised before closing, and the filing shows zero Ordinary Shares and options remaining afterward.
Centessa Pharmaceuticals director Francesco De Rubertis reported indirect dispositions of Ordinary Shares in connection with Eli Lilly’s acquisition of the company. All reported holdings, held through various Medicxi investment funds, were automatically transferred at the effective time of a UK Scheme of Arrangement, leaving zero shares reported after the transactions. Under the deal, each Ordinary Share or ADS became entitled to receive $38.00 in cash per share plus one contingent value right, which can pay up to an additional $9.00 per share if specified milestones are achieved. The Form 4 notes that De Rubertis disclaims beneficial ownership of the Medicxi-held shares except for any pecuniary interest.
Centessa Pharmaceuticals plc director Mary Lynne Hedley reported the disposition to the issuer of multiple share option awards on June 24, 2026. The transactions reflect the closing of a deal in which Eli Lilly and Company, through a wholly owned subsidiary, acquired all outstanding Ordinary Shares of Centessa by a UK scheme of arrangement.
At the effective time of this scheme, each outstanding Centessa share option, whether vested or unvested, was automatically cancelled and converted into the right to receive cash plus a contingent value right. For each underlying Ordinary Share, holders became entitled to $38.00 in cash minus the option’s exercise price, and one non-transferable contingent value right that may pay up to an additional $9.00 per Ordinary Share if specified milestones are achieved. No share options were exercised before this effective time, and the filing shows Ms. Hedley’s covered options now have zero remaining balances.
Centessa Pharmaceuticals plc director Arjun Goyal reported automatic dispositions of his interests in the company in connection with its acquisition by Eli Lilly and Company. All outstanding Ordinary Shares were acquired through a UK court-approved scheme of arrangement.
At the effective time of the scheme, holders of Ordinary Shares became entitled to receive $38.00 in cash per share, plus one non-transferable contingent value right (CVR) that may pay up to an additional $9.00 per share if specified milestones are achieved. Goyal reported the transfer of 462,585 Ordinary Shares held indirectly through Vinyanshu Ventures LLC and the cancellation of several share option grants, which converted into cash-plus-CVR rights. The transfers and cancellations occurred automatically under the transaction agreement, and no options were exercised beforehand.
Centessa Pharmaceuticals director Carol Stuckley reported the cancellation of multiple share options in connection with Eli Lilly’s acquisition of the company. On June 24, 2026, Eli Lilly, through a wholly owned subsidiary, acquired all outstanding Ordinary Shares of Centessa by a scheme of arrangement under UK law.
Five option grants, each over Ordinary Shares with exercise prices of $12.43, $8.89, $6.35, $4.87, and $9.42, were disposed of to the issuer. Following these transactions, each outstanding share option was cancelled and converted into the right to receive $38.00 in cash per underlying share plus one contingent value right (CVR) per share, with potential additional payments of up to $9.00 per share based on specified milestones. No share options were exercised before the effective time.
Hukkelhoven Mathias reported disposition transactions in this Form 4 filing.
Centessa Pharmaceuticals director Mathias Hukkelhoven reported the cancellation of several share option awards following the acquisition of Centessa by Eli Lilly and Company. Under a UK scheme of arrangement, Eli Lilly’s subsidiary acquired all outstanding Ordinary Shares of Centessa.
At the effective time, each outstanding share option, whether or not vested, was automatically cancelled and converted into a cash payment equal to $38.00 per underlying Ordinary Share minus the option’s exercise price, plus one contingent value right per share. These contingent value rights may pay up to an additional $9.00 per Ordinary Share upon achievement of specified milestones. No share options were exercised before this conversion, and no derivative options remain reported after the transaction.
Weinhoff Gregory M reported disposition transactions in this Form 4 filing.
Centessa Pharmaceuticals plc has been acquired by Eli Lilly and Company, and Chief Business Officer Gregory M. Weinhoff’s equity was automatically cashed out as part of the deal. All 65,925 Ordinary Shares reported were transferred to the acquirer through a UK court-approved scheme of arrangement.
At the effective time, each Ordinary Share became entitled to $38.00 in cash plus a non-transferable contingent value right (CVR) for potential additional payments of up to $9.00 per share, subject to specified milestones. The same per-share terms applied to American Depositary Shares.
All outstanding Restricted Share Units first became fully vested, then were cancelled and converted into the same mix of $38.00 cash and one CVR per underlying share. All reported share options, including those with exercise prices between $3.85 and $25.19, were cancelled and converted into cash equal to $38.00 minus the exercise price per option share, plus one CVR per underlying Ordinary Share.
ZBAR BRETT I W reported disposition transactions in this Form 4 filing.
Centessa Pharmaceuticals plc director Dr. Brett I. W. Zbar reported the cancellation of multiple share option awards in connection with Centessa’s acquisition by Eli Lilly and Company. On June 24, 2026, Eli Lilly, through its subsidiary LDH XV Corporation, acquired all outstanding Ordinary Shares of Centessa by a UK scheme of arrangement under a Transaction Agreement dated March 31, 2026.
At the effective time of the scheme, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive cash equal to the excess of $38.00 per share over the option’s exercise price, plus one non-transferable contingent value right (CVR) per underlying Ordinary Share, allowing potential additional payments of up to an aggregate $9.00 per share if specified milestones are achieved. No share options were exercised before the effective time. The filing notes that the options granted to Dr. Zbar are held solely for the benefit of General Atlantic Service Company, L.P., and he disclaims beneficial ownership except for any pecuniary interest.
Centessa Pharmaceuticals plc director Samarth Kulkarni reported the cancellation of several share option grants in connection with Eli Lilly and Company’s acquisition of Centessa. On June 24, 2026, all outstanding share options were disposed of to the issuer and converted into cash and contingent value rights.
Pursuant to the transaction terms, each option was cancelled and converted into the right to receive cash equal to $38.00 per underlying Ordinary Share minus the option’s exercise price, plus one non-transferable contingent value right per share. Each contingent value right may pay up to an aggregate of $9.00 per Ordinary Share upon specified milestones. No share options were exercised before the effective time.
Centessa Pharmaceuticals plc reported that Chief Executive Officer Mario Alberto Accardi had 604 Ordinary Shares withheld by the company to satisfy tax obligations arising from the vesting of restricted share units. This was a tax-withholding disposition, not an open-market trade. Following the withholding, he directly holds 243,282 Ordinary Shares, which may be represented by American Depositary Shares on a one-for-one basis.
Centessa Pharmaceuticals Chief People Officer Karen M. Anderson exercised options and sold shares in a planned transaction. She exercised options to acquire 41,076 Ordinary Shares at an exercise price of $8.01 per share, then sold 41,076 Ordinary Shares in open‑market trades at a weighted average price of $30.1242 per share, with individual sale prices ranging from $29.99 to $30.44. The sale was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 12, 2025. After these transactions, Anderson directly holds 62,085 Ordinary Shares, which may be represented by American Depositary Shares on a one‑for‑one basis.
Centessa Pharmaceuticals’ Chief Business Officer Gregory M. Weinhoff exercised stock options and sold shares in a routine, pre-planned transaction. He exercised options to acquire 23,998 Ordinary Shares at $3.85 per share, then sold 23,998 Ordinary Shares at $30.00 per share in an open‑market transaction.
The sale was executed under a Rule 10b5‑1 trading plan adopted on November 12, 2025, indicating it was pre‑scheduled rather than timed discretionarily. Following these transactions, Weinhoff directly holds 65,925 Ordinary Shares.
Centessa Pharmaceuticals plc Chief People Officer Karen M. Anderson exercised stock options and sold shares in a planned transaction. On March 16–17, 2026, she exercised options for 74,811 Ordinary Shares at an exercise price of $4.01 per share and received the same number of shares.
She then sold 64,768 shares at a weighted average price of $28.2079 on March 16, 2026 and 10,043 shares at a weighted average price of $28.1002 on March 17, 2026, totaling 74,811 shares sold. After these transactions, she directly owns 62,085 Ordinary Shares. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025.
Centessa Pharmaceuticals plc Chief People Officer Karen M. Anderson reported an exercise-and-sell transaction in the company’s Ordinary Shares. She exercised share options covering 109,398 Ordinary Shares at exercise prices of $4.01 and $3.85 per share, converting them into Ordinary Shares.
On the same date, she sold a total of 120,029 Ordinary Shares in open-market transactions at weighted average prices of $26.1505 and $27.1328 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025. Following these transactions, she directly holds 62,085 Ordinary Shares.
Centessa Pharmaceuticals plc Chief People Officer Karen M. Anderson exercised stock options and sold shares in a planned transaction. She exercised options for 109,398 Ordinary Shares at an exercise price of $4.01 per share and received the same number of Ordinary Shares.
On the same date, she sold 107,961 Ordinary Shares at a weighted average price of $26.1505 and 12,068 Ordinary Shares at a weighted average price of $27.1328, in multiple trades within stated price ranges. These sales were made under a Rule 10b5-1 trading plan adopted on November 12, 2025.
After these transactions, Anderson directly holds 62,085 Ordinary Shares. The exercised option, originally granted with vesting beginning on December 1, 2023, is now fully exercised, and no remaining derivative position from this option is shown in this filing.
Centessa Pharmaceuticals Chief Business Officer Gregory M. Weinhoff sold 73,196 Ordinary Shares of CNTA in open-market transactions. The sales occurred on March 13, 2026 at weighted average prices of $26.1668 and $27.1570 per share across multiple trades within disclosed price ranges.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025, indicating they were scheduled in advance. Following these sales, Weinhoff continues to hold 65,925 Ordinary Shares directly.
Centessa Pharmaceuticals plc reported that its Chief Medical Officer, Stephen Kanes, received an equity grant in the form of restricted share units. On February 2, 2026, he was awarded 120,000 Ordinary Shares at a price of $0 per share, bringing his directly held beneficial ownership to 120,000 Ordinary Shares.
The award consists of RSUs issued under Centessa’s Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one Ordinary Share. The RSUs will vest and be settled in four equal annual installments, with the first installment vesting on February 2, 2027, aligning compensation with long‑term company performance.
Centessa Pharmaceuticals awarded its Chief Financial Officer, John J. Crowley, new equity incentives. He received 45,000 Ordinary Shares as restricted share units that vest in four equal annual installments starting on February 2, 2027. The company also granted a share option for 181,000 Ordinary Shares with an exercise price of $25.19, expiring on February 2, 2036. This option vests in 48 equal monthly installments, beginning on March 2, 2026. These grants increase his direct beneficial ownership to 45,000 shares and 181,000 options, aligning his compensation more closely with the company’s future share performance.
Centessa Pharmaceuticals plc’s Chief Accounting Officer, Raphael Deferiere, reported new equity awards. On February 2, 2026, he received 11,000 Ordinary Shares as Restricted Share Units at $0 cost, bringing his directly held Ordinary Shares to 11,000.
He was also granted a share option for 42,000 Ordinary Shares at an exercise price of $25.19 per share, expiring on February 2, 2036. These options vest in equal monthly installments over 48 months starting March 2, 2026, while the RSUs vest in four equal annual installments beginning February 2, 2027.
Centessa Pharmaceuticals' Chief Legal Officer J Iqbal Hussain reported multiple equity transactions in Centessa Pharmaceuticals plc Ordinary Shares. On January 30, 2026, he sold 1,010 Ordinary Shares at a weighted average price of $25.0109. On February 1, 2026, 7,780 shares were withheld to cover tax obligations tied to vesting restricted share units at $24.57 per share.
On February 2, 2026, he sold an additional 38,951 Ordinary Shares at a weighted average price of $25.151, and received 40,000 restricted share units that vest in four equal annual installments starting February 2, 2027, plus 20,000 restricted share units that vest on February 2, 2027. He also received a share option for 160,000 Ordinary Shares at an exercise price of $25.19, vesting monthly over 48 months starting March 2, 2026. After these transactions, he directly beneficially owned 117,645 Ordinary Shares and indirectly 5,500 Ordinary Shares through his spouse, in addition to the 160,000-share option.
Centessa Pharmaceuticals’ Chief Business Officer Gregory M. Weinhoff reported new equity compensation and related share withholding. On February 1, 2026, 14,158 ordinary shares were withheld at $24.57 each to cover taxes on vesting restricted share units, leaving 108,121 shares owned directly.
On February 2, 2026, he received 31,000 restricted share units at $0, bringing his direct holdings to 139,121 ordinary shares. These RSUs vest in four equal annual installments starting February 2, 2027. He also was granted a share option for 123,000 ordinary shares at an exercise price of $25.19, vesting in 48 equal monthly installments beginning March 2, 2026 and expiring February 2, 2036.
Centessa Pharmaceuticals’ Chief Executive Officer Mario Alberto Accardi reported routine equity compensation and related tax withholding transactions in the company’s ordinary shares.
On February 1, 2026, 2,915 ordinary shares were withheld by Centessa to cover tax obligations tied to restricted share unit vesting, leaving him with 175,886 shares held directly. On February 2, 2026, he received 68,000 restricted share units for no cash cost, increasing his directly held ordinary shares to 243,886. The RSUs vest in four equal annual installments starting February 2, 2027.
Also on February 2, 2026, he was granted a share option for 273,000 ordinary shares at an exercise price of $25.19 per share. The option vests in equal monthly installments over 48 months, with the first installment vesting on March 2, 2026. Following this grant, he beneficially owns 273,000 options directly. Each ordinary share may be represented by one American Depositary Share.
Centessa Pharmaceuticals Chief People Officer Karen M. Anderson reported routine equity compensation and related tax withholding. On February 1, 2026, the company withheld 10,606 Ordinary Shares at a price of $24.57 per share to satisfy tax obligations on vesting restricted share units, leaving her with 43,716 directly owned Ordinary Shares.
On February 2, 2026, she received 29,000 Restricted Share Units under the company’s 2021 Stock Option and Incentive Plan, bringing her direct Ordinary Share holdings to 72,716. These RSUs vest in four equal annual installments starting February 2, 2027. She was also granted a share option for 117,000 Ordinary Shares at an exercise price of $25.19 per share, vesting in equal monthly installments over 48 months starting March 2, 2026, with an expiration date of February 2, 2036.
Centessa Pharmaceuticals reported insider equity activity for Chief Technology & Quality Officer Tia L. Bush. On February 1, 2026, the company withheld 8,549 Ordinary Shares at $24.57 per share to satisfy tax obligations tied to vesting restricted share units.
On February 2, 2026, Bush received 35,000 Restricted Share Units at no cost, each representing one Ordinary Share, which will vest in four equal annual installments starting February 2, 2027. On the same date, she was also granted a share option for 140,000 Ordinary Shares at an exercise price of $25.19 per share, vesting in 48 equal monthly installments beginning March 2, 2026 and expiring on February 2, 2036. Following these transactions, she directly owned 147,954 Ordinary Shares and 140,000 share options.
Centessa Pharmaceuticals plc (CNTA) reported an insider transaction by its General Counsel on a Form 4. On 11/17/2025, the officer exercised a share option to buy 6,000 Ordinary Shares at $5.84 per share and, on the same day, sold 6,000 Ordinary Shares at a weighted average price of $27.6392 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 14, 2024. Following these transactions, the officer directly owns 105,386 Ordinary Shares and holds 221,559 share options beneficially. Each Ordinary Share may be represented by an American Depositary Share on the market.
Centessa Pharmaceuticals plc (CNTA) reported an insider equity transaction by its Chief Technology & Quality Officer. On 11/17/2025, the officer exercised a share option covering 40,000 Ordinary Shares at an exercise price of $9.42 per share and, on the same date, sold 40,000 Ordinary Shares at a price of $28 per share under a Rule 10b5-1 trading plan adopted on September 14, 2024. After these transactions, the officer directly owned 121,503 Ordinary Shares and held 360,338 derivative securities (share options) beneficially.
Centessa Pharmaceuticals (CNTA) reported an insider equity update. The company’s Officer (President, Orexin Program) filed a Form 4 showing a tax withholding transaction tied to vested restricted share units. On 11/01/2025, 593 Ordinary Shares were withheld under code F at $24.9 per share to satisfy taxes. Following this administrative withholding, the insider’s beneficial ownership is 193,801 Ordinary Shares, held directly. The filing notes each American Depositary Share currently represents one Ordinary Share.
Centessa Pharmaceuticals (CNTA) reported an insider transaction by its President, Orexin Program. On 10/27/2025, the officer exercised 5,000 options at $8.01 and sold 8,000 ordinary shares at $25. Following these transactions, the reporting person beneficially owned 194,394 shares (direct). The sales were effected under a Rule 10b5-1 trading plan adopted on February 14, 2025. The filer also reported 30,000 derivative securities (options) remaining. Each ADS currently represents one ordinary share.
Centessa Pharmaceuticals plc (CNTA) disclosed an insider transaction by its General Counsel. On 10/15/2025, the officer exercised 6,000 share options at $5.84 and sold 6,000 ordinary shares at a $22.4065 weighted average price pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2024. Following these transactions, the officer reported 105,386 ordinary shares held directly and 5,500 held indirectly by a spouse, and 227,559 derivative securities (options) beneficially owned. The company notes its Ordinary Shares may be represented by ADSs, each currently equal to one Ordinary Share.
Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals plc (CNTA), reported insider transactions on 09/24/2025. The filing shows the exercise of a stock option to acquire 35,000 ordinary shares at an exercise price of $9.42 and a contemporaneous sale of 35,000 ordinary shares at $24.00 executed under a Rule 10b5-1 trading plan adopted on 09/14/2024. After the non-derivative transactions the filing lists 156,503 shares beneficially owned following the acquisition and 121,503 shares following the sale. The related option covers 35,000 underlying ordinary shares, is exercisable in accordance with the stated vesting schedule, has an exercise price of $9.42 and an expiration date of 05/07/2031. The Form 4 is signed by an attorney-in-fact, Raphael Deferiere, dated 09/24/2025.
Mario Alberto Accardi, President, Orexin Program at Centessa Pharmaceuticals plc (CNTA), reported two sales of Ordinary Shares on 09/16/2025 executed under a Rule 10b5-1 trading plan adopted February 14, 2025. The Form 4 shows a disposition of 7,430 shares at a weighted-average price of $21.3333, leaving 198,136 shares beneficially owned, and a disposition of 742 shares at a weighted-average price of $22.0213, leaving 197,394 shares beneficially owned. The filing notes Ordinary Shares may be represented by American Depositary Shares on a one-for-one basis and provides price ranges for the multiple transactions comprising each weighted average.